Irinotecan in Colorectal Cancer: Pharmacokinetics and Genetic Factors
Author Information
Author(s): Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, Laurand A, Poirier A-L, Morel A, Chatelut E, Robert J, Gamelin E
Primary Institution: Laboratoire d'Oncopharmacologie, Centre Paul-Papin, France
Hypothesis
This study aims to establish relationships between genetic and non-genetic factors affecting the pharmacokinetics of irinotecan and its efficacy and toxicity.
Conclusion
The study found that UGT1A1 genotyping and cortisol 6β-hydroxylation could help determine the optimal dose of irinotecan for colorectal cancer patients.
Supporting Evidence
- UGT1A1 polymorphism was significantly associated with plasma bilirubin levels.
- Patients with variant UGT1A1 alleles had a higher risk of neutropenia.
- Cortisol 6β-hydroxylation predicted the occurrence of diarrhea.
- Significant correlations were found between biological parameters and pharmacokinetic parameters.
Takeaway
Doctors can use genetic tests to figure out the best dose of a cancer medicine called irinotecan, which helps make sure patients get the right amount without too many side effects.
Methodology
The study included 49 patients with metastatic colorectal cancer, analyzing pharmacokinetics and genetic polymorphisms related to irinotecan metabolism.
Potential Biases
Potential biases may arise from the small sample size and the specific patient population studied.
Limitations
The study did not establish direct relationships between pharmacokinetic parameters and clinical outcomes.
Participant Demographics
34 males and 15 females, median age 60 years.
Statistical Information
P-Value
p=0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website